Proactive Investors - Run By Investors For Investors

Uscom granted medical device sales certification in China

The medical technology company specialises in the development and marketing of premium non-invasive cardiovascular and pulmonary medical devices.
USCOM 1A is a non-invasive haemodynamic monitor

Uscom Ltd’s (ASX:UCM) Chinese subsidiary has been granted a Type II Medical Device Business Registration Certificate in China.

Uscom China can now sell all type II medical devices including USCOM 1A, Uscom BP+ and SpiroSonic digital ultrasonic spirometers, directly into the Chinese market.

While all current Uscom business in China is based on USCOM 1A sales, Uscom currently has USCOM 1A in a re-approval cycle, and the Uscom BP+ and the SpiroSonic series of devices in their initial Chinese NMPA regulatory process.

This new certification provides a platform for the direct sale of these devices following the completion of these regulatory approvals.

Building a long-term business in China

Uscom China now has a registered Beijing office with a Business License, a Foreign Trade Registration Record, a VAT General Taxpayer Qualification Form, a Certificate of Customs Declaration and full capital and trading bank facilities.

Uscom executive chairman Associate Professor Rob Phillips said: “We are not just selling products into China, we are building a long-term business in China based on a new business model.

“Following this certification we can now import, support and sell medical devices independently as we bring our seven new products to the Chinese market.


“As our NMPA submissions progress, we are preparing by building the on-ground resources to expand operations in the China market.

“We are also focused on expanding our current distribution, to create a wide-reaching sales organisation that can cover the expansive geography of China.”

View full UCM profile View Profile

Uscom Ltd Timeline

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
An illustration of Ozop's BLIF technique
March 31 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use